Fig. 1: Evaluation of multiple myeloma (MM) cell line responses to Cf treatment.
From: Proteasome inhibition blocks necroptosis by attenuating death complex aggregation
a Viability of indicated MM cell lines 22 h post treatment (hpt) with TNF + cycloheximide + zVADfmk (T/CH/V) measured by CellTiterGlow assay of four replicate wells per data point, either alone or in combination with 3 µM RIPK3 inhibitor GSK’840 (G840), or 3 µM RIPK1 inhibitor GSK’963 (G963), or 10 µM human MLKL-specific inhibitor necrosulfonamide (NSA). *p v  < 0.05, **p v  < 0.005, ***p v  < 0.0005. b Viability of MM cells 22 hpt with Cf either alone, or in combination with V, G840 or both together. c Immunoblot (IB) for phospho-MLKL (p)MLKL and Casp8 cleavage product P18 (P18-C8) in 1% Triton-soluble (Sol.) and -insoluble (Pellet) fractions of RPMI8226 cells 8 hpt with Cf, Cf/V, T/CH or T/CH/V. β-actin is used as a loading control. d Viability of KMS-18 cells 22 hpt with Cf alone, Cf/V, or in combination with the pan serine protease-inhibitor TLCK as indicated
